The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or “the Company”) (NASDAQ: BTAI) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. BioXcel disclosed on June 29, 2023, that it has opened an investigation into the data integrity and protocol adherence of a trial site connected to its TRANQUILITY II clinical trial. The Company also warned that recent developments related to its Phase 3 trial may “impact the timing of the Company’s development plans for, and prospects for regulatory approval.” Based on this news, shares of BioXcel fell as much as 66% in intraday trading.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230629277353/en/